Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00592-022-01866-3.pdf
Reference33 articles.
1. Singh JA, Gaffo A (2020) Gout epidemiology and comorbidities. Semin Arthritis Rheum 50:S11–S16. https://doi.org/10.1016/j.semarthrit.2020.04.008
2. Khanna D, Fitzgerald JD, Khanna PP et al (2012) 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446. https://doi.org/10.1002/acr.21772
3. Li M, Hu X, Fan Y et al (2016) Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose–response meta-analysis. Sci Rep 6:19520. https://doi.org/10.1038/srep19520
4. Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122. https://doi.org/10.1186/1471-2369-15-122
5. Thottam GE, Krasnokutsky S, Pillinger MH (2017) Gout and metabolic syndrome: a tangled web. Curr Rheumatol Rep 19:60. https://doi.org/10.1007/s11926-017-0688-y
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Managing Gout in Patients with Metabolic Syndrome;Drugs & Aging;2024-07-27
2. SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum;Clinical Therapeutics;2024-07
3. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin;JAMA Internal Medicine;2024-06-01
4. Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers;Kidney International Reports;2024-06
5. Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials;Clinical Therapeutics;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3